(Q38124438)

English

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

scientific article published on July 2013

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

29 August 2017

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance (English)

1 reference

stated in

Europe PubMed Central

29 August 2017

1

Laurence Zitvogel

0 references

Guido Kroemer

series ordinal

4

object named as

Guido Kroemer

0 references

Lorenzo Galluzzi

series ordinal

2

object named as

Lorenzo Galluzzi

0 references

Mark J. Smyth

series ordinal

3

object named as

Mark J Smyth

1 reference

stated in

Europe PubMed Central

PubMed ID

23890065

retrieved

29 August 2017

language of work or name

English

0 references

publication date

1 July 2013

1 reference

stated in

Europe PubMed Central

29 August 2017

1 reference

Europe PubMed Central

29 August 2017

39

1 reference

stated in

Europe PubMed Central

29 August 2017

1

1 reference

stated in

Europe PubMed Central

29 August 2017

74-88

1 reference

stated in

Europe PubMed Central

29 August 2017

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

1 reference

9 February 2024

https://opencitations.net/index/api/v1/citations/10.1172/JCI66236

Identifiers

DOI

10.1016/J.IMMUNI.2013.06.014

1 reference

stated in

Europe PubMed Central

29 August 2017

1 reference

Europe PubMed Central

PubMed ID

23890065

retrieved

29 August 2017

ResearchGate publication ID

253332277

0 references

(Q38124438)

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)